| scholarly article | Q13442814 |
| P2093 | author name string | Andrew H Talal | |
| Charles S Venuto | |||
| P2860 | cites work | Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014. | Q38596178 |
| Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro | Q39044226 | ||
| The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. | Q39349116 | ||
| Clearance approaches in pharmacology. | Q39765862 | ||
| Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. | Q41121436 | ||
| Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms | Q42207349 | ||
| In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters | Q44299143 | ||
| Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients | Q45397719 | ||
| Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients | Q45405415 | ||
| Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters | Q47248395 | ||
| Effect of telaprevir on the pharmacokinetics of midazolam and digoxin | Q48204557 | ||
| Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. | Q50579007 | ||
| Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition | Q79374419 | ||
| Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides | Q24564462 | ||
| Review and management of drug interactions with boceprevir and telaprevir | Q24628716 | ||
| Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment | Q26751452 | ||
| Pharmacokinetic drug interactions in liver disease: An update | Q26774479 | ||
| Drug-drug interactions during antiviral therapy for chronic hepatitis C | Q26864887 | ||
| Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease | Q27473126 | ||
| Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C | Q27480302 | ||
| Interferon signaling and treatment outcome in chronic hepatitis C | Q27486083 | ||
| Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection | Q28262594 | ||
| Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response | Q33597579 | ||
| Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome | Q33944295 | ||
| Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes | Q34504820 | ||
| Elbasvir/Grazoprevir: First Global Approval | Q34516975 | ||
| Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction | Q34819051 | ||
| Telaprevir-based treatment effects on hepatitis C virus in liver and blood | Q35129251 | ||
| Altered Hepatic Blood Flow and Drug Disposition1 | Q35372340 | ||
| Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin | Q35862941 | ||
| Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors | Q36018848 | ||
| Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial | Q36048957 | ||
| Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells | Q36290604 | ||
| Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients | Q36468240 | ||
| Gene expression analysis in serial liver fine needle aspirates | Q36487934 | ||
| Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir | Q36571969 | ||
| The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection | Q36944050 | ||
| Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin | Q37026626 | ||
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Q37042094 | ||
| Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers | Q37067118 | ||
| Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir | Q37257317 | ||
| Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver | Q37504548 | ||
| Insight into tissue unbound concentration: utility in drug discovery and development | Q38061181 | ||
| Species differences in drug transporters and implications for translating preclinical findings to humans | Q38068912 | ||
| Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. | Q38155591 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 169-175 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
| P1476 | title | Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology | |
| P478 | volume | 6 |
Search more.